

Supporting Information

Discovery of 3-hydroxy-3-pyrrolin-2-one-based mPGES-1 inhibitors using a multi-step virtual screening protocol

Gianluigi Lauro,^a Vincenza Cantone,^a Marianna Potenza,^a Katrin Fischer,^b Andreas Koeberle,^b
Oliver Werz,^b Raffaele Riccio,^a and Giuseppe Bifulco^{a,*}

^aDepartment of Pharmacy, University of Salerno, via Giovanni Paolo II 132, 84084 Fisciano, Italy

^bDepartment of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-
University Jena, Philosophenweg 14, D-07743 Jena, Germany

*To whom correspondence should be addressed: bifulco@unisa.it, Telephone: +39 (0)89 969741

List of Contents

Figures S1-S8 ¹H NMR spectra of compounds **1-8** S1-S9

Figure S9 Analytical reversed-phase HPLC of compounds **2** (A) and **3** (B).... S10

Figure S1. ¹H NMR spectrum of compound 1, as provided by Otava Ltd.




Figure S2. ¹H NMR spectrum of compound 2, as provided by Otava Ltd.




Figure S3. ¹H NMR spectrum of compound 3, as provided by Otava Ltd.




Figure S4. ¹H NMR spectrum of compound 4, as provided by Otava Ltd.




Figure S5. ^1H NMR spectrum of compound **5**, as provided by Otava Ltd.




Figure S6. ¹H NMR spectrum of compound **6**, as provided by Otava Ltd.




Figure S7. ¹H NMR spectrum of compound 7, as provided by Otava Ltd.




Figure S8. ^1H NMR spectrum of compound **8**, as provided by Otava Ltd.





Figure S9. Analytical reversed-phase HPLC of compounds **2** (A) and **3** (B).

A



B

